Literature DB >> 30476351

Factors Associated With Cysticidal Treatment Response in Extraparenchymal Neurocysticercosis.

Rocio Osorio1,2, Roger Carrillo-Mezo3, Matthew L Romo4, Andrea Toledo1, Carlos Matus1,2, Iliana González-Hernández5, Helgi Jung5, Agnès Fleury1,2.   

Abstract

Extraparenchymal neurocysticercosis is the most severe form of cysticercosis, and response to treatment is suboptimal. We sought to determine how demographic and clinical characteristics and albendazole sulfoxide concentrations were related to cysticidal treatment response. We conducted a longitudinal study of 31 participants with extraparenchymal vesicular parasites who received the same treatment, albendazole 30 mg/kg/day for 10 days with dexamethasone 0.4 mg/kg/day for 13 days, followed by a prednisone taper. Response to treatment was determined by parasite volumes before and 6 months after treatment. Eight participants (25.8%) had a complete treatment response, 16 (51.6%) had a treatment response > 50% but < 100%, and 7 (22.6%) had a treatment response < 50%. Complete treatment response was significantly associated with higher concentrations of albendazole sulfoxide (P = .032), younger age (P = .032), fewer cysts (P = .049) and lower pretreatment parasite volume (P = .037). Higher number of previous cysticidal treatment courses was associated with a noncomplete treatment response (P = .023). Although the large proportion of participants with less than a complete response emphasizes the need to develop more efficacious pharmacologic regimens, the association of albendazole sulfoxide concentrations with treatment response highlights the importance of optimizing existing therapeutic regimens. In addition, the association of treatment response with parasite volume emphasizes the importance of early diagnosis.
© 2018, The American College of Clinical Pharmacology.

Entities:  

Keywords:  Mexico; Taenia solium; albendazole; corticosteroids; neurocysticercosis; treatment

Mesh:

Substances:

Year:  2018        PMID: 30476351     DOI: 10.1002/jcph.1346

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  7 in total

1.  A Novel, Highly Sensitive Quantitative Polymerase Chain Reaction Assay for the Diagnosis of Subarachnoid and Ventricular Neurocysticercosis and for Assessing Responses to Treatment.

Authors:  Elise M O'Connell; Sarah Harrison; Eric Dahlstrom; Theodore Nash; Thomas B Nutman
Journal:  Clin Infect Dis       Date:  2020-04-15       Impact factor: 9.079

2.  A longitudinal analysis of albendazole treatment effect on neurocysticercosis cyst evolution using multistate models.

Authors:  Michelle A Montgomery; Marcel Ramos; Elizabeth A Kelvin; Arturo Carpio; Alexander Jaramillo; W Allen Hauser; Hongbin Zhang
Journal:  Trans R Soc Trop Med Hyg       Date:  2019-12-01       Impact factor: 2.184

3.  A recombinant monoclonal-based Taenia antigen assay that reflects disease activity in extra-parenchymal neurocysticercosis.

Authors:  Madelynn Corda; Joshua Sciurba; Jiana Blaha; Siddhartha Mahanty; Adriana Paredes; Hector H Garcia; Theodore E Nash; Thomas B Nutman; Elise M O'Connell
Journal:  PLoS Negl Trop Dis       Date:  2022-05-26

Review 4.  Taenia solium Cysticercosis and Its Impact in Neurological Disease.

Authors:  Hector H Garcia; Armando E Gonzalez; Robert H Gilman
Journal:  Clin Microbiol Rev       Date:  2020-05-27       Impact factor: 26.132

5.  Natural History of Treated Subarachnoid Neurocysticercosis.

Authors:  Theodore E Nash; Elise M O'Connell; Dima A Hammoud; Lauren Wetzler; JeanAnne M Ware; Siddhartha Mahanty
Journal:  Am J Trop Med Hyg       Date:  2020-01       Impact factor: 2.345

Review 6.  Neurocysticercosis: Current Perspectives on Diagnosis and Management.

Authors:  Caitlin Butala; T M Brook; Ayodele O Majekodunmi; Susan Christina Welburn
Journal:  Front Vet Sci       Date:  2021-05-10

Review 7.  Subarachnoid neurocysticercosis: emerging concepts and treatment.

Authors:  Theodore E Nash; Elise M O'Connell
Journal:  Curr Opin Infect Dis       Date:  2020-10       Impact factor: 4.968

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.